Abstract
Background and aims Non-alcoholic fatty liver disease (NAFLD) is a complex trait that has a global prevalence estimated as 25%. We aimed to identify the genetic variant underlying a four-generation family with progressive NAFLD leading to cirrhosis, decompensation and development of hepatocellular carcinoma in the absence of common risk factors such as obesity and type 2 diabetes.
Methods Exome sequencing and genome comparisons were used to identify the likely causal variant. We extensively characterised the clinical phenotype and post-prandial metabolic responses of family members with the identified novel variant in comparison to healthy non-carriers and wild type patients with NAFLD. Variant-expressing hepatocyte-like cells (HLCs) were derived from human induced pluripotent stem cells generated from homozygous donor skin fibroblasts. The phenotype was assessed using imaging, targeted RNA analysis and molecular expression arrays.
Results We identified a rare causal variant in MTTP, c.1691T>C p.I564T (rs745447480) encoding microsomal triglyceride transfer protein (MTP) associated with progressive non-alcoholic fatty liver disease, unrelated to metabolic syndrome. Although other described mutations in MTTP cause abetalipoproteinemia, neither homozygotes nor heterozygotes exhibited characteristic manifestations of this severe disease. HLCs derived from a homozygote donor had lower lipoprotein ApoB secretion, compared to wild type cells. Cytoplasmic triglyceride accumulation in HLCs triggered endoplasmic reticulum stress, secretion of pro-inflammatory mediators and production of reactive oxygen species.
Conclusion We have identified and characterized a rare causal variant in MTTP and homozygosity for MTTP p.I564T is associated with progressive NAFLD without any other manifestations of abetalipoproteinemia.
Competing Interest Statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; Guruprasad Aithal has received unrelated research grants from Pfizer Inc, and served as a consultant and an advisory board member for Pfizer Inc, GlaxoSmithKline and Median Technologies and is President of the British Association for the Study of the Liver; Louise Wain has received unrelated research grants from GlaxoSmithKline and Orion Pharma Ltd; Martin Tobin has unrelated research collaborations with GlaxoSmithKline and Orion Pharma Ltd; Ioanna Ntalla is employed by Gilead Sciences Ltd. (since August 2019). no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work was supported by the Medical Research Council Nottingham Molecular Pathology Node [grant number MR/N005953/1], National Institute of Health Research Nottingham Digestive Diseases Biomedical Research Unit and Nottingham Biomedical Research Centre [BRC-1215-20003]. All cell modelling was supported by the RoseTrees Trust and the Stoneygate Trust [M546]. L. Wain holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was supported by the NIHR Leicester Biomedical Research Centre; C. John holds a Medical Research Council Clinical Research Training Fellowship [MR/P00167X/1]. The exome sequencing was funded by MRC Grant Senior Clinical Fellowship to M. Tobin (G0902313) and we thank the high-throughput genomics group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust Grant 090532/Z/09/Z and MRC Hub Grant G090074791070) for the generation of the sequence data. M. Tobin is supported by a Wellcome Trust Investigator Award [WT202849/Z/16/Z] and holds an NIHR Senior Investigator Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The meal-response study was approved by the Health Research Authority after review by National Research Ethics Service Committee North-East (Ref 16/NE/0251) and was sponsored by Nottingham University Hospitals NHS Trust. The Genetics of Rare Inherited Disorders (GRID) study was approved by the Health Research Authority after review by National Research Ethics Service East Midlands Northampton Committee (Ref 12/EM/0262).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵e Senior Authors
Conflicts of Interest Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; Guruprasad Aithal has received unrelated research grants from Pfizer Inc, and served as a consultant and an advisory board member for Pfizer Inc, GlaxoSmithKline and Median Technologies and is President of the British Association for the Study of the Liver; Louise Wain has received unrelated research grants from GlaxoSmithKline and Orion Pharma Ltd; Martin Tobin has unrelated research collaborations with GlaxoSmithKline and Orion Pharma Ltd; Ioanna Ntalla is employed by Gilead Sciences Ltd. (since August 2019). no other relationships or activities that could appear to have influenced the submitted work.
Data Availability
The data that support the findings of this study are available on request from the corresponding author. Exome sequence data will be available for restricted access via The European Genome-phenome Archive.
